Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
P/B ratio for Kymera Therapeutics, Inc. (KYMR)
P/B ratio as of 2023: 3.76
According to Kymera Therapeutics, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 3.76. At the end of 2022 the company had a P/B ratio of 2.75.
P/B ratio history for Kymera Therapeutics, Inc. from 2018 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 3.76 |
| 2022 | 2.75 |
| 2021 | 6.63 |
| 2020 | 3.79 |
| 2019 | -19.91 |
| 2018 | -19.45 |